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Introduction: Two previous cases of the development of Dupuytren’s contractures were reported in association
with BRAF inhibitor treatment for BRAF V600E mutation-positive metastatic melanoma and metastatic papillary
thyroid carcinoma. We reported on a third case with a slower onset of presentation.
Case presentation: A 66-year-old white man was diagnosed with a BRAF V600E mutated metastatic cutaneous
melanoma. He was commenced on oral vemurafenib 960mg twice daily. A marked response was achieved for
his metastatic disease. He noticed a change of his hair characteristics and a feeling of “lumps” in both palms by
6 months. By 9 months, classical Dupuytren’s contracture was apparent.
Conclusions: Dupuytren’s contracture is not a known side effect of BRAF inhibitor treatment. The timeline for
the development of Dupuytren’s contracture on BRAF inhibitor treatment is not well defined. Although the etiology
of Dupuytren’s contracture is unknown, an increase in tumor necrosis factor has been demonstrated to be a possible
mechanism. BRAF inhibition has been shown to increase immune reaction in the tumor microenvironment and is
associated with high serum tumor necrosis factor level. We propose that an increased level of tumor necrosis factor
associated with BRAF inhibition may increase the risk of the development of Dupuytren’s contractures.
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Vemurafenib, an oral anti-BRAF V600 kinase inhibitor,
is indicated for the treatment of advanced malignant
melanoma for patients whose tumors harbor the BRAF
V600 mutation. Vemurafenib inhibits the MAP kinase
pathway by binding to the kinase domain in mutant
BRAF and has been shown to prolong both progression
free and overall survival [1].
Toxicity from vemurafenib is common and includes
many cutaneous side effects (skin rash, photosensitivity,
hyperkeratosis, cutaneous squamous cell carcinoma,
keratoacanthoma, and skin papilloma), alopecia, arthralgia,
headache, fatigue, diarrhea and nausea [2–4].
Recently two cases of Dupuytren’s contractures have
been reported in the medical literature in patients re-
ceiving a BRAF inhibitor [5, 6]. We report on an add-
itional case, different in development when compared to
the cases previously published.* Correspondence: dr.szewai.chan@gmail.com
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creativecommons.org/publicdomain/zero/1.0/Case presentation
A 66-year-old white man was diagnosed with a BRAF
V600E mutated metastatic cutaneous melanoma with
subcutaneous metastases. He was known to have asthma
for which he needed salbutamol and fluticasone inhalers.
He had no other medical history of note. He was en-
rolled onto a national clinical trial and after signing an
informed consent he was commenced on oral vemurafe-
nib 960mg twice daily. A marked response was achieved
(complete response) and his metastatic subcutaneous
lesion disappeared after 5 months. He experienced grade 1
side effects such as arthralgia, a macular non-itchy skin
rash over his upper chest, photosensitivity in sun exposed
areas and general malaise. The appearance of hyperkera-
totic lesions, keratoacanthomas and one basal cell carcin-
oma were treated with excisions, without a need to change
his planned treatment dose.
Approximately 6 months after the start of vemurafenib
treatment, he noticed a change in his hair characteristics
to curly hair (Fig. 1) and he started to feel “lumps” in
both of his palms. By 9 months, most of his skin rashccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Development of curly hair on vemurafenib treatment
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noticeable and harder.
A clinical examination demonstrated painless nodules
in both palms and formation of a fibrous band proximal
to his 4th and 5th digits, consistent with a diagnosis of
Dupuytren’s contractures (Fig. 2). There was no func-
tional impairment with finger extension.
As he remained asymptomatic, a watch and wait
approach was adopted with continuation of vemurafenib
therapy.
Discussion
Dupuytren’s contracture is a benign, slowly progressive
fibrosis of the palmar fascia. It is a result of fibroblastic
proliferation and disorderly collagen deposition. TheFig. 2 Development of fibrous band and palmar nodules suggestive
of Dupuytren’s contracturesearly proliferative stage is associated with painless or
painful nodules in the palms. With continued fibrosis, it
will progress to form longitudinal bands or cords, limit-
ing finger extension. Thumb and index fingers are usu-
ally spared and 4th and 5th fingers are commonly
affected.
The etiology of Dupuytren’s contracture is unknown.
Most patients present over the age of 50; it is more com-
mon in relatives of affected patients, male gender and
people of European descent [7, 8]. There was no defini-
tive association with a history of cigarette smoking,
alcohol consumption or repetitive handling tasks. Our
patient’s occupation was office-based and he enjoys
gardening, fishing and golf.
On review of the current available medical literature,
the first reported case of Dupuytren’s contractures sec-
ondary to BRAF kinase inhibitor therapy was reported
by Bicknell et al. [5]. The described patient had a BRAF
mutation-positive metastatic papillary thyroid carcinoma
and was treated with a BRAF inhibitor on a clinical trial
and developed Dupuytren’s contractures of both hands,
palmar hyperkeratosis, a keratosis pilaris-like eruption
and erythema nodosum [5].
Our patient presented with classical features of
Dupuytren’s contractures such as palmar nodules and
fibrous band formation, of a slow onset, manifesting
at 6 months after commencement of vemurafenib
treatment. He had neither flexion contractures nor
functional impairment and his dosage of vemurafenib
was not interrupted or discontinued.
This is also very different from a patient described by
Sibaud and Chevreau where there was an abrupt onset
of Dupuytren’s contractures after 6 weeks of vemurafe-
nib treatment for metastatic melanoma with metastatic
cervical lymph nodes [6]. The patient had a rapid devel-
opment of fixed digital flexion contractures and visible
cords but no associated palmar nodules. Discontinuation
of vemurafenib was necessary due to the rapidly pro-
gressive nature and functional impairment affecting
activities of daily living. There was however, no improve-
ment or deterioration at 3 months after discontinuation
of vemurafenib [6].
Dupuytren’s contracture is not a known side effect
resulting from the BRAF kinase inhibitor vemurafenib.
Sibaud and Chevreau hypothesized that vemurafenib
induces a paradoxical proliferation in wild type-BRAF
myofibroblasts [6]. BRAF inhibition has been shown to
increase immune reaction in the tumor microenviron-
ment. Wilmott et al. demonstrated that BRAF inhibitor-
treated patients with metastatic melanoma have higher
serum levels of interferon-γ (IFN-γ), CCL4, and tumor
necrosis factor (TNF) [9]. Verjee et al. have shown that
significant numbers of immune cells and a high level of
pro-inflammatory cytokines are found in Dupuytren’s
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blasts from the palms of patients with Dupuytren’s
contractures into myofibroblasts via activation of the
Wnt signaling pathway. Neutralizing antibodies to TNF
reverse this phenomenon, suggesting that TNF inhibition
may prevent progression or recurrence of Dupuytren’s
contractures [10].
We propose that an increased level of TNF associated
with BRAF inhibition may increase the risk of the devel-
opment of Dupuytren’s contractures.
Conclusions
The slow onset of the development of Dupuytren’s con-
tracture in our patient suggested that the timeline for
the development of Dupuytren’s contracture is not well
defined on BRAF inhibitor treatment. An increased level
of TNF associated with BRAF inhibition may increase
the risk of the development of Dupuytren’s contractures.
We need to be vigilant on this rare side effect through-
out the course of the BRAF inhibitor treatment.
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